iNOS Antibody - #AF0199

(113)   (84)  
Product: iNOS Antibody
Catalog: AF0199
Description: Rabbit polyclonal antibody to iNOS
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat
Mol.Wt.: 130kDa; 131kD(Calculated).
Uniprot: P35228
RRID: AB_2833391

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:3000, IHC 1:50-1:200, IF/ICC: 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Clonality:
Polyclonal
Specificity:
iNOS Antibody detects endogenous levels of total iNOS.
RRID:
AB_2833391
Cite Format: Affinity Biosciences Cat# AF0199, RRID:AB_2833391.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

HEP-NOS; Hepatocyte NOS; HEPNOS; inducible; Inducible nitric oxide synthase; Inducible NO synthase; Inducible NOS; iNOS; MAC NOS; Macrophage NOS; Nitric oxide synthase 2 inducible; Nitric oxide synthase 2 inducible macrophage; nitric oxide synthase 2A (inducible, hepatocytes); Nitric oxide synthase; Nitric oxide synthase inducible; nitric oxide synthase, macrophage; NOS 2; NOS; Nos II; NOS type II; nos2; NOS2_HUMAN; NOS2A; NOS2A, Inducible, Hepatocyte; Peptidyl-cysteine S-nitrosylase NOS2;

Immunogens

Immunogen:
Uniprot:

P35228(NOS2_HUMAN) >>Visit HPA database.

Gene(ID):
NOS2(4843)
Expression:
P35228 NOS2_HUMAN:

Expressed in the liver, retina, bone cells and airway epithelial cells of the lung. Not expressed in the platelets.

Description:
iNOS Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In macrophages, NO mediates tumoricidal and bactericidal actions. Belongs to the NOS family. Induced by endotoxins and cytokines. Induced by interferon gamma acting synergistically with lipopolysaccharide, tumor necrosis factor alpha or interleukin-1 beta. Homodimer. Binds SLC9A3R1. 2 isoforms of the human protein are produced by alternative splicing.
Sequence:
MACPWKFLFKTKFHQYAMNGEKDINNNVEKAPCATSSPVTQDDLQYHNLSKQQNESPQPLVETGKKSPESLVKLDATPLSSPRHVRIKNWGSGMTFQDTLHHKAKGILTCRSKSCLGSIMTPKSLTRGPRDKPTPPDELLPQAIEFVNQYYGSFKEAKIEEHLARVEAVTKEIETTGTYQLTGDELIFATKQAWRNAPRCIGRIQWSNLQVFDARSCSTAREMFEHICRHVRYSTNNGNIRSAITVFPQRSDGKHDFRVWNAQLIRYAGYQMPDGSIRGDPANVEFTQLCIDLGWKPKYGRFDVVPLVLQANGRDPELFEIPPDLVLEVAMEHPKYEWFRELELKWYALPAVANMLLEVGGLEFPGCPFNGWYMGTEIGVRDFCDVQRYNILEEVGRRMGLETHKLASLWKDQAVVEINIAVLHSFQKQNVTIMDHHSAAESFMKYMQNEYRSRGGCPADWIWLVPPMSGSITPVFHQEMLNYVLSPFYYYQVEAWKTHVWQDEKRRPKRREIPLKVLVKAVLFACMLMRKTMASRVRVTILFATETGKSEALAWDLGALFSCAFNPKVVCMDKYRLSCLEEERLLLVVTSTFGNGDCPGNGEKLKKSLFMLKELNNKFRYAVFGLGSSMYPRFCAFAHDIDQKLSHLGASQLTPMGEGDELSGQEDAFRSWAVQTFKAACETFDVRGKQHIQIPKLYTSNVTWDPHHYRLVQDSQPLDLSKALSSMHAKNVFTMRLKSRQNLQSPTSSRATILVELSCEDGQGLNYLPGEHLGVCPGNQPALVQGILERVVDGPTPHQTVRLEALDESGSYWVSDKRLPPCSLSQALTYFLDITTPPTQLLLQKLAQVATEEPERQRLEALCQPSEYSKWKFTNSPTFLEVLEEFPSLRVSAGFLLSQLPILKPRFYSISSSRDHTPTEIHLTVAVVTYHTRDGQGPLHHGVCSTWLNSLKPQDPVPCFVRNASGFHLPEDPSHPCILIGPGTGIAPFRSFWQQRLHDSQHKGVRGGRMTLVFGCRRPDEDHIYQEEMLEMAQKGVLHAVHTAYSRLPGKPKVYVQDILRQQLASEVLRVLHKEPGHLYVCGDVRMARDVAHTLKQLVAAKLKLNEEQVEDYFFQLKSQKRYHEDIFGAVFPYEAKKDRVAVQPSSLEMSAL

PTMs - P35228 As Substrate

Site PTM Type Enzyme
S50 Phosphorylation
S70 Phosphorylation
T77 Phosphorylation
S112 Phosphorylation
S124 Phosphorylation
T126 Phosphorylation
Y151 Phosphorylation P12931 (SRC)
Y267 Phosphorylation
Y270 Phosphorylation
S425 Phosphorylation
Y446 Phosphorylation
Y451 Phosphorylation
S453 Phosphorylation
K516 Ubiquitination
Y575 Phosphorylation
K604 Acetylation
R670 Methylation
S745 Phosphorylation P27361 (MAPK3)
Y868 Phosphorylation
S892 Phosphorylation
S898 Phosphorylation
Y1055 Phosphorylation P12931 (SRC)
Y1123 Phosphorylation
Y1134 Phosphorylation

Research Backgrounds

Function:

Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In macrophages, NO mediates tumoricidal and bactericidal actions. Also has nitrosylase activity and mediates cysteine S-nitrosylation of cytoplasmic target proteins such PTGS2/COX2 (By similarity). As component of the iNOS-S100A8/9 transnitrosylase complex involved in the selective inflammatory stimulus-dependent S-nitrosylation of GAPDH on 'Cys-247' implicated in regulation of the GAIT complex activity and probably multiple targets including ANXA5, EZR, MSN and VIM. Involved in inflammation, enhances the synthesis of proinflammatory mediators such as IL6 and IL8.

PTMs:

Polyubiquitinated; mediated by SPSB1, SPSB2 and SPSB4, leading to proteasomal degradation.

Subcellular Location:

Cytoplasm>Cytosol.
Note: Localizes as discrete foci scattered throughout the cytosol and in the presence of SPSB1 and SPSB4, exhibits a more diffuse cytosolic localization.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed in the liver, retina, bone cells and airway epithelial cells of the lung. Not expressed in the platelets.

Subunit Structure:

Homodimer. Interacts with SLC9A3R1. Interacts with GAPDH; induced by oxidatively-modified low-densitity lipoprotein (LDL(ox)). Interacts with S100A8 and S100A9 to form the iNOS-S100A8/9 transnitrosylase complex. Interacts with SPSB1, SPSB2 and SPSB4. Interacts with ELOC and CUL5 in the presence of SPSB1 or SPSB2 or SPSB4.

Family&Domains:

Belongs to the NOS family.

Research Fields

· Cellular Processes > Transport and catabolism > Peroxisome.   (View pathway)

· Environmental Information Processing > Signal transduction > Calcium signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > HIF-1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Apelin signaling pathway.   (View pathway)

· Human Diseases > Infectious diseases: Bacterial > Salmonella infection.

· Human Diseases > Infectious diseases: Bacterial > Pertussis.

· Human Diseases > Infectious diseases: Parasitic > Leishmaniasis.

· Human Diseases > Infectious diseases: Parasitic > Chagas disease (American trypanosomiasis).

· Human Diseases > Infectious diseases: Parasitic > Toxoplasmosis.

· Human Diseases > Infectious diseases: Parasitic > Amoebiasis.

· Human Diseases > Infectious diseases: Bacterial > Tuberculosis.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Small cell lung cancer.   (View pathway)

· Metabolism > Amino acid metabolism > Arginine biosynthesis.

· Metabolism > Amino acid metabolism > Arginine and proline metabolism.

· Metabolism > Global and overview maps > Metabolic pathways.

· Organismal Systems > Endocrine system > Relaxin signaling pathway.

References

1). Efficient Therapy of Inflammatory Bowel Disease (IBD) with Highly Specific and Durable Targeted Ta2C Modified with Chondroitin Sulfate (TACS). Advanced Materials, 2023 (PubMed: 37224059) [IF=29.4]

Application: WB    Species: Mouse    Sample: RAW264.7 cells

Figure 7.TACS relieves inflammation and restores intestinal barrier function. B)WB analysis of COX-2 and iNOS proteins expression in RAW264.7 cells with different treatments.
2). A novel Nanocellulose-Gelatin-AS-IV external stent resists EndMT by activating autophagy to prevent restenosis of grafts. Bioactive Materials, 2023 (PubMed: 36330163) [IF=18.9]
3). Plasma Membrane-Derived Biomimetic Apoptotic Nanovesicles Targeting Inflammation and Cartilage Degeneration for Osteoarthritis. Small methods, 2024 (PubMed: 39036830) [IF=12.4]
4). Arsenic retention in erythrocytes and excessive erythrophagocytosis is related to low selenium status by impaired redox homeostasis. Redox Biology, 2022 (PubMed: 35500533) [IF=11.4]
5). Ganoderma lucidum polysaccharide modulates gut microbiota and immune cell function to inhibit inflammation and tumorigenesis in colon. Carbohydrate Polymers, 2021 (PubMed: 34119183) [IF=11.2]
6). Aligned electrospun poly(l-lactide) nanofibers facilitate wound healing by inhibiting macrophage M1 polarization via the JAK-STAT and NF-κB pathways. JOURNAL OF NANOBIOTECHNOLOGY, 2022 (PubMed: 35883095) [IF=10.2]

Application: WB    Species: Mice    Sample:

Fig. 2 The effect of aligned nanofibers on macrophage polarization. A Phalloidin staining of macrophages on electrospun membranes. Actin is stained green, and the nucleus is stained blue. B Flow cytometric analysis of macrophages. C qPCR analysis of M2 polarization-related genes. D ELISA analysis of IL-4 secretion. E qPCR analysis of M1 polarization-related genes (*p < 0.05, **p < 0.01, ***p < 0.001, n = 3). F Western blot analysis of macrophage polarization-related proteins. G and H Immunofluorescence analysis of CD86 and CD206 expression in macrophages. CD86 and CD206 are stained red, and the nucleus is stained blue
7). Dually Crosslinked Copper‐Poly (Tannic Acid) Nanoparticles with Microenvironment‐Responsiveness for Infected Wound Treatment. Advanced Healthcare Materials, 2023 (PubMed: 36842067) [IF=10.0]
8). Antifibrotic Effects of Tetrahedral Framework Nucleic Acids by Inhibiting Macrophage Polarization and Macrophage-myofibroblast Transition in Bladder Remodeling. Advanced Healthcare Materials, 2023 (PubMed: 36603196) [IF=10.0]
9). Dual delivery of an NF-κB inhibitor and IL-10 through supramolecular hydrogels polarizes macrophages and promotes cardiac repair after myocardial infarction. Acta Biomaterialia, 2023 (PubMed: 37001840) [IF=9.7]
10). Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer. Cancer Letters, 2023 (PubMed: 37146936) [IF=9.7]
Load more

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.